A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Efficacy of NVA237 (50 ug o.d.) Using Tiotropium (5 ug o.d.) as an Active Control in Brazilian Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

Trial Profile

A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Efficacy of NVA237 (50 ug o.d.) Using Tiotropium (5 ug o.d.) as an Active Control in Brazilian Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Glycopyrrolate (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 19 Aug 2016 Status changed from suspended to withdrawn prior to enrolment.
    • 13 Jan 2014 Planned initiation date changed from 1 Oct 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
    • 13 Jan 2014 Planned End Date changed from 1 Nov 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top